| Followers | 74 |
| Posts | 3928 |
| Boards Moderated | 0 |
| Alias Born | 03/23/2013 |
Tuesday, November 26, 2024 10:13:32 AM
2 ominous charts. You and all who liked your childish name calling post might want to check out these charts:
XBI
The index has been buried below the ice line since it plunged below at the beginning of 2022 - 3 years ago! At the right edge, we see another significant support/trendline break, followed by a backtest on feeble volume. This presents a short entry opportunity - forecasting further decline in biotech stocks.
Conclusion? The wind is not at your back.
AMRN
No, the "bottom is not in", therefore any buys are counter-trend and usually result in catching a falling knife.
The chart shows intermediate and long term down trends with 6 heavy points of overhead resistance.
For the stock price to emerge above 1.00/share, it will somehow have to trade through all of these areas of strong resistance where massive selling emerges to pound the stock to lower lows.
What are these 6 areas?
1 - 20DMA
2- 50DMA and upper down trending channel line
3- October low
4- 200dMA
5- ice line
6- long term DOWN trendline.
If that isn't bad enough, look at momentum. 3 times in the past year the MACD has been rejected at the 0 line (red arrows).
This is a very poor long trade when faced with these resisting TA headwinds.
I've got news for you bullrunner, your posts every 10min announcing you "BOUGHT MORE SHARES!" will not change these charts. No amount of smearing of my opinion will either. But again, knock yourself out. I find it entertaining
BTW, are you John Hancock re-emerged with another aliaa??
XBI
The index has been buried below the ice line since it plunged below at the beginning of 2022 - 3 years ago! At the right edge, we see another significant support/trendline break, followed by a backtest on feeble volume. This presents a short entry opportunity - forecasting further decline in biotech stocks.
Conclusion? The wind is not at your back.
AMRN
No, the "bottom is not in", therefore any buys are counter-trend and usually result in catching a falling knife.
The chart shows intermediate and long term down trends with 6 heavy points of overhead resistance.
For the stock price to emerge above 1.00/share, it will somehow have to trade through all of these areas of strong resistance where massive selling emerges to pound the stock to lower lows.
What are these 6 areas?
1 - 20DMA
2- 50DMA and upper down trending channel line
3- October low
4- 200dMA
5- ice line
6- long term DOWN trendline.
If that isn't bad enough, look at momentum. 3 times in the past year the MACD has been rejected at the 0 line (red arrows).
This is a very poor long trade when faced with these resisting TA headwinds.
I've got news for you bullrunner, your posts every 10min announcing you "BOUGHT MORE SHARES!" will not change these charts. No amount of smearing of my opinion will either. But again, knock yourself out. I find it entertaining
BTW, are you John Hancock re-emerged with another aliaa??
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
